每经AI快讯，1月22日，恩华药业(002262.SZ)公告称，公司近日获得国家药品监督管理局核准签发的化 学药品右酮洛芬氨丁三醇注射液的《药品注册证书》。该药品是一种非甾体抗炎镇痛药，作为阿片类镇 痛药的辅助，用于成人不适合口服给药的急性中度至重度术后疼痛。右酮洛芬氨丁三醇注射液为公司首 个围手术期注射用非甾体抗炎药（NSAIDs），其上市销售将对公司今后业绩的提升产生积极的影响。 ...

恩华药业1月22日公告，公司近日获得国家药品监督管理局核准签发的化学药品右酮洛芬氨丁三醇注射 液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是COX-1 和COX-2 活性 的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度术后疼痛。 ...

格隆汇1月22日丨恩华药业(002262.SZ)公布，公司于近日获得国家药品监督管理局核准签发的化学药品 右酮洛芬氨丁三醇注射液的《药品注册证书》，右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是 COX-1和COX-2活性的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度 术后疼痛。本品镇痛效果和安全性良好，可明显减少术后阿片类药物的用量。根据国家药品监督管理局 药品数据显示，目前该品种国内只有南京正科医药股份有限公司获得批准。 ...

恩华药业公告，公司于近日获得国家药品监督管理局核准签发的化学药品右酮洛芬氨丁三醇注射液的 《药品注册证书》。右酮洛芬氨丁三醇注射液为公司首个围手术期注射用非甾体抗炎药（NSAIDs）， 本次获得右酮洛芬氨丁三醇注射液的《药品注册证书》，丰富了公司在镇痛用药领域的产品管线，有利 于提升公司的市场竞争力，其上市销售将对公司今后业绩的提升产生积极的影响。 ...

恩华药业公告称，近日获国家药监局核准签发的化学药品右酮洛芬氨丁三醇注射液《药品注册证书》， 规格为2ml:50mg，剂型为注射剂，有效期24个月，批准文号有效期至2031年1月13日。该药品是一种非 甾体抗炎镇痛药，用于成人不适合口服给药的急性中度至重度术后疼痛。这是公司首个围手术期注射用 非甾体抗炎药，丰富了产品管线，将提升市场竞争力和业绩。不过，生产销售可能受不确定因素影响。 ...

智通财经APP讯，恩华药业(002262.SZ)公告，公司近日获得国家药品监督管理局核准签发的化学药品右 酮洛芬氨丁三醇注射液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药，是 COX-1和COX-2活性的抑制剂，作为阿片类镇痛药的辅助，用于成人不适合口服给药的急性中度至重度 术后疼痛。 ...

江苏恩华药业股份有限公司 关于完成工商变更及备案登记手续并换发营业执照的公告 证券代码：002262 证券简称：恩华药业 公告编号：2026-001 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 江苏恩华药业股份有限公司（以下简称：公司）于2025年12月19日召开了2025年 第二次临时股东大会及职工代表大会2025年第二次会议，分别审议通过了《关于取消 监事会、变更经营范围、增加董事会人数、修订<公司章程>并办理工商变更登记的议 案》、《关于补选1名独立董事的议案》及《关于选举职工代表董事的议案》，具体内 容详见公司于2025年12月20日在《证券时报》和巨潮资讯网（www.cninfo.com.cn）披 露的《2025年第二次临时股东大会决议公告》（公告编号：2025-060）、《关于监事 会改革、选举职工代表董事的公告》（公告编号：2025-061）。 一、变更及备案登记情况 董事会根据公司2025年第二次临时股东大会决议的相关授权及要求，于2026年1月 14日向徐州市政务服务管理办公室申请办理上述事项的变更及备案登记手续。 2026年1月20日，公司 ...

Core Viewpoint - The company, Enhua Pharmaceutical, is actively participating in national drug procurement activities to achieve favorable outcomes for its products, focusing on the development, production, and sales of central nervous system (CNS) drugs [1] Group 1: Company Overview - Enhua Pharmaceutical is the only publicly listed company in China dedicated to the research and production of CNS drugs [1] - The company is a designated production base for anesthetic and psychiatric drugs in China [1] - Enhua's product line covers a wide range of CNS drugs, including those for schizophrenia, depression, and analgesia [1] Group 2: Product Portfolio - The company has the most comprehensive product line in the CNS drug sector in China, with 60 approved new drug formulations and 98 product specifications [1] - Enhua holds 7 exclusive products and has 15 first-to-market products [1] - The company has the highest market share in 29 of its products nationwide [1]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].